Topical Azithromycin and oral doxycycline in meibomian gland dysfunction

Comparison of the efficacy of topical azithromycin with oral doxycycline in the treatment of meibomian gland dysfunction: A randomized clinical practice trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220607055097N3

Enrollment

Registered

2022-08-30

Start date

2019-12-01

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meibomian gland dysfunction. Blepharitis

Interventions

Intervention 1: Intervention group: Topical Azithromycin 1%, Twice daily for 1 week followed by once daily for 3 weeks. Intervention 2: Intervention group: Oral Doxycycline 100 mg, once daily for 4 we

Eligibility

Sex/Gender

All

Age

26 Years to 42 Years

Inclusion criteria

Inclusion criteria: All the patients within the specified age group with posterior blepharitis secondary to meibomian gland dysfunction Patients with meibomian gland dysfunction, non responsive to conventional therapy such as lid massage, warm compresses and lid scrubbing

Exclusion criteria

Exclusion criteria: Patients with blepharitis other than posterior one Patients with other inflammatory lid conditions like atopic blepharoconjunctivitis Patients with traumatic eyelid injuries Patients with neoplastic lid disorders Pregnant, conceiving and lactating females history of any allergy to the study drugs Patients treated with oral or topical medications other than study drugs for posterior blepharitis within 3 months period

Design outcomes

Primary

Measure	Time frame
Mean improvement in symptoms score. Timepoint: Baseline, 2nd and 4th week. Method of measurement: Subjective symptoms including itchy eyes, grittiness, MG plugging, foreign body (FB) sensation and watering were recorded in a check list as 0 = asymptomatic, 1= moderate and 2 = severe symptoms.;Mean improvement in corneal staining. Timepoint: Baseline, 2nd and 4th week. Method of measurement: For corneal staining, we divided the cornea into five regions and assigned a score of 1 for peripheral staining and 4 for staining of central cornea implying more severe involvement by the disease process.;Mean improvement in bulbar conjunctival hyperaemia. Timepoint: Baseline, 2nd and 4th week. Method of measurement: For bulbar conjunctival hyperaemia, area was divided into six regions and scoring from 0 to 4 was done depending upon the number of involved regions.;Mean improvement in Schirmer 1 test. Timepoint: Baseline, 2nd and 4th week. Method of measurement: Schemers 1 test (5 min. test without anesthesia) were performed in all of the participants, > 10 mm wetting was considered as normal.	—

Measure

Time frame

Mean improvement in symptoms score. Timepoint: Baseline, 2nd and 4th week. Method of measurement: Subjective symptoms including itchy eyes, grittiness, MG plugging, foreign body (FB) sensation and watering were recorded in a check list as 0 = asymptomatic, 1= moderate and 2 = severe symptoms.;Mean improvement in corneal staining. Timepoint: Baseline, 2nd and 4th week. Method of measurement: For corneal staining, we divided the cornea into five regions and assigned a score of 1 for peripheral staining and 4 for staining of central cornea implying more severe involvement by the disease process.;Mean improvement in bulbar conjunctival hyperaemia. Timepoint: Baseline, 2nd and 4th week. Method of measurement: For bulbar conjunctival hyperaemia, area was divided into six regions and scoring from 0 to 4 was done depending upon the number of involved regions.;Mean improvement in Schirmer 1 test. Timepoint: Baseline, 2nd and 4th week. Method of measurement: Schemers 1 test (5 min. test without anesthesia) were performed in all of the participants, > 10 mm wetting was considered as normal.

—

Countries

Pakistan

Contacts

Public ContactAdnan Ahmad

Nowshera Medical College, Nowshera

dradnanahmad@hotmail.com+92 91 2586506

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026